Literature DB >> 20354541

Radiotherapy: PSA nadir predicts long-term mortality.

Mark K Buyyounouski1.   

Abstract

The effect of PSA level on distant metastases and cause-specific mortality was assessed in a recent study, and showed a nadir PSA level 1.5 ng/ml within 2 years of radiotherapy treatment predicts distant metastases and death from prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20354541     DOI： 10.1038/nrclinonc.2010.33

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  8 in total

1.  Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy.

Authors:  S X Cavanaugh; C D Fuller; P A Kupelian; C Reddy; P Bradshaw; B H Pollock; M Fuss
Journal:  Prostate Cancer Prostatic Dis       Date:  2005       Impact factor: 5.554

2.  Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.

Authors:  Mark K Buyyounouski; Alexandra L Hanlon; Eric M Horwitz; Robert G Uzzo; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

3.  Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.

Authors:  Michael E Ray; Larry B Levy; Eric M Horwitz; Patrick A Kupelian; Alvaro A Martinez; Jeff M Michalski; Thomas M Pisansky; Michael J Zelefsky; Anthony L Zietman; Deborah A Kuban
Journal:  Urology       Date:  2006-12-04       Impact factor: 2.649

4.  Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate.

Authors:  A L Zietman; M K Tibbs; K C Dallow; C T Smith; A F Althausen; R A Zlotecki; W U Shipley
Journal:  Radiother Oncol       Date:  1996-08       Impact factor: 6.280

5.  Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death.

Authors:  Pino Alcantara; Alexandra Hanlon; Mark K Buyyounouski; Eric M Horwitz; Alan Pollack
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

6.  Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.

Authors:  Michael J Zelefsky; Weiji Shi; Yoshiya Yamada; Marisa A Kollmeier; Brett Cox; Jessica Park; Venkatraman E Seshan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-08       Impact factor: 7.038

7.  Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy.

Authors:  Mark K Buyyounouski; Alexandra L Hanlon; Eric M Horwitz; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-04       Impact factor: 7.038

8.  Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.

Authors:  W R Lee; A L Hanlon; G E Hanks
Journal:  J Urol       Date:  1996-08       Impact factor: 7.450
  8 in total
  2 in total

1.  PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition.

Authors:  Tracy L Klayton; Karen Ruth; Mark K Buyyounouski; Robert G Uzzo; Yu-Ning Wong; David Y T Chen; Mark Sobczak; Ruth Peter; Eric M Horwitz
Journal:  Pract Radiat Oncol       Date:  2011

2.  Single-Center Evaluation of Treatment Success Using Two Different Protocols for MRI-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer.

Authors:  Gencay Hatiboglu; Valentin Popeneciu; David Bonekamp; Mathieu Burtnyk; Robert Staruch; Florian Distler; Jan Philipp Radtke; Johann Motsch; Heinz Peter Schlemmer; Sascha Pahernik; Joanne Nyarangi-Dix
Journal:  Front Oncol       Date:  2021-10-27       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.